For approximately 3.4 million Americans living with epilepsy, nearly one-third continue to experience seizures despite the use of medication.
While many patients achieve seizure control through standard pharmaceuticals, nearly one-third of the 3.4 million people diagnosed with the disorder continue to experience recurring seizures despite trying at least two appropriately selected antiseizure drugs. This persistent gap in treatment efficacy is the focus of a new push during National Epilepsy Awareness Month to reframe how patients and providers view surgical intervention.
According to Dr. Samrina Hanif, a neurologist at the Marshall Health Network and director of the epilepsy program at Cabell Huntington Hospital, medical professionals and patients alike must move past the outdated notion that surgery is a last-resort option. Writing on November 15, 2026, Hanif said that patients who have failed to gain control after two medication trials should be referred for a comprehensive epilepsy evaluation sooner rather than later.
The stakes for these patients involve more than just seizure frequency. Uncontrolled epilepsy often limits employment opportunities, driving, and personal independence. By identifying the specific neurological origin of seizures, clinicians can now offer a suite of interventions that move well beyond the limitations of daily pill regimens.
Modern Surgical Options for Seizure Control
Neuroscience has evolved rapidly, moving away from invasive procedures toward highly targeted, minimally invasive techniques. For patients whose seizure focus is identifiable, resective surgery remains a primary option, involving the removal of the specific brain tissue responsible for producing seizures. For others, less invasive technologies provide alternatives to traditional open-brain surgery.
Laser Ablation, or LITT, utilizes MRI-guided laser technology to destroy seizure-generating tissue without the need for extensive incisions. Similarly, clinicians are increasingly using Stereo-EEG, or SEEG-RFTC, to place precise electrodes that map the brain’s electrical activity. Once the source is identified, these electrodes can perform radiofrequency ablation to neutralize the area.
For patients who are not candidates for tissue removal, neuromodulation offers a different path. These implanted devices act as a bridge between technology and biology:
- Vagus Nerve Stimulation (VNS): Delivers regular electrical impulses to help dampen seizure activity.
- Responsive Neurostimulation (RNS): A smart device that monitors brain waves for abnormal activity and triggers a targeted electrical response when a seizure begins.
- Deep Brain Stimulation (DBS): Uses electrodes implanted in specific brain regions to regulate the neural networks involved in seizure propagation.
Regional Access to Specialized Care
The shift toward these advanced treatments is gaining momentum through institutional recognition. Cabell Huntington Hospital’s Epilepsy and Seizure Center is currently designated by the National Association of Epilepsy Centers as a level 3 center. This classification indicates that the facility is equipped to handle complex diagnostic evaluations and provide the multidisciplinary care required for surgical planning.
“Epilepsy surgery may not be suitable for everyone, but for selected patients, it can significantly reduce seizures, restore independence and sometimes achieve seizure freedom, said Dr. Samrina Hanif.”
Working in tandem with Dr. Heather Pinckard-Dover, the director of stereotactic and functional neurosurgery at Marshall Health Network and an associate professor of neurosurgery at the Marshall University Joan C. Edwards School of Medicine, the team aims to bring these high-level services to patients across the Tri-State region. This specialized approach—combining video EEG monitoring with individualized treatment planning—differs from the trial-and-error method often used in long-term medication management.
While surgery offers the potential for significant improvement, it is not a universal fix. The decision to proceed involves a rigorous evaluation process to ensure that the risks of an intervention do not outweigh the potential benefits. For those who have reached the limits of pharmacological options, however, the availability of these surgical pathways means that the conversation about their health is no longer closed.
As the medical community marks November as a time to raise awareness, the core message remains clear. If two medications have failed to provide the necessary control, the next step may not be another prescription, but a consultation with a surgical specialist.